Eubel Brady & Suttman Asset Management Inc. Has $24.59 Million Stock Position in Zimmer Biomet Holdings, Inc. $ZBH

Eubel Brady & Suttman Asset Management Inc. decreased its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 6.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 273,475 shares of the medical equipment provider’s stock after selling 19,274 shares during the period. Zimmer Biomet accounts for approximately 2.8% of Eubel Brady & Suttman Asset Management Inc.’s portfolio, making the stock its 13th biggest position. Eubel Brady & Suttman Asset Management Inc.’s holdings in Zimmer Biomet were worth $24,591,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of ZBH. Key Financial Inc boosted its position in Zimmer Biomet by 164.6% during the third quarter. Key Financial Inc now owns 262 shares of the medical equipment provider’s stock valued at $26,000 after purchasing an additional 163 shares during the last quarter. Cullen Frost Bankers Inc. boosted its position in Zimmer Biomet by 66.7% during the third quarter. Cullen Frost Bankers Inc. now owns 290 shares of the medical equipment provider’s stock valued at $29,000 after purchasing an additional 116 shares during the last quarter. Root Financial Partners LLC acquired a new stake in Zimmer Biomet during the third quarter valued at $31,000. Flagship Harbor Advisors LLC acquired a new stake in Zimmer Biomet during the fourth quarter valued at $32,000. Finally, Grove Bank & Trust boosted its position in Zimmer Biomet by 431.6% during the fourth quarter. Grove Bank & Trust now owns 404 shares of the medical equipment provider’s stock valued at $36,000 after purchasing an additional 328 shares during the last quarter. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Trading Up 1.3%

Zimmer Biomet stock opened at $83.73 on Friday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.95 and a current ratio of 1.73. The business’s 50-day simple moving average is $89.60 and its 200-day simple moving average is $91.52. The firm has a market capitalization of $16.20 billion, a PE ratio of 21.75, a PEG ratio of 1.94 and a beta of 0.48. Zimmer Biomet Holdings, Inc. has a 52 week low of $79.12 and a 52 week high of $108.29.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Tuesday, April 28th. The medical equipment provider reported $2.09 EPS for the quarter, topping analysts’ consensus estimates of $1.86 by $0.23. The business had revenue of $2.09 billion for the quarter, compared to analyst estimates of $2.07 billion. Zimmer Biomet had a return on equity of 13.24% and a net margin of 9.05%.The firm’s revenue for the quarter was up 9.3% on a year-over-year basis. During the same period in the previous year, the company posted $1.81 earnings per share. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. Equities research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.47 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, April 30th. Stockholders of record on Tuesday, March 31st were paid a $0.24 dividend. The ex-dividend date was Tuesday, March 31st. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.1%. Zimmer Biomet’s payout ratio is presently 24.94%.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on ZBH. Leerink Partners initiated coverage on Zimmer Biomet in a research report on Monday, April 13th. They set a “hold” rating and a $101.00 price objective for the company. TD Cowen raised Zimmer Biomet from a “hold” rating to a “buy” rating in a research report on Monday, January 26th. Stifel Nicolaus reduced their price target on Zimmer Biomet from $110.00 to $105.00 and set a “buy” rating for the company in a research report on Wednesday, April 29th. Wells Fargo & Company reduced their price target on Zimmer Biomet from $98.00 to $90.00 and set an “equal weight” rating for the company in a research report on Wednesday, April 29th. Finally, UBS Group reaffirmed a “sell” rating and issued a $89.00 price target on shares of Zimmer Biomet in a research report on Wednesday, February 11th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, twelve have issued a Hold rating and three have given a Sell rating to the company. According to MarketBeat, Zimmer Biomet presently has a consensus rating of “Hold” and a consensus target price of $102.80.

Insider Activity at Zimmer Biomet

In other news, SVP Lori Winkler sold 2,650 shares of Zimmer Biomet stock in a transaction dated Thursday, March 12th. The stock was sold at an average price of $94.66, for a total value of $250,849.00. Following the transaction, the senior vice president directly owned 10,224 shares in the company, valued at approximately $967,803.84. The trade was a 20.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 1.28% of the company’s stock.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.